

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : A61K 31/445	A1	(11) International Publication Number: WO 00/24396 (43) International Publication Date: 4 May 2000 (04.05.00)
<p>(21) International Application Number: PCT/US99/24502</p> <p>(22) International Filing Date: 20 October 1999 (20.10.99)</p> <p>(30) Priority Data: 60/105,712 27 October 1998 (27.10.98) US</p> <p>(71) Applicant (for all designated States except US): ALCON LABORATORIES, INC. [US/US]; 6201 South Freeway, Fort Worth, TX 76134 (US).</p> <p>(72) Inventors; and (75) Inventors/Applicants (for US only): COLLIER, Robert, J., Jr. [US/US]; 3701 Big Bear Lake Drive, Arlington, TX 76016 (US). HELLBERG, Mark, R. [US/US]; 5211 Overridge Drive, Arlington, TX 76017 (US). KAPIN, Michael, A. [US/US]; 3602 Silkwood Trail, Arlington, TX 76016 (US). BARNES, George, E. [US/US]; 2205 Coolidge Drive, Arlington, TX 76011 (US). CHANDLER, Michael, L. [US/US]; 720 Cardinal Court, Crowley, TX 76036 (US).</p> <p>(74) Agents: YEAGER, Sally, S. et al.; R & D Counsel Q-148, Alcon Laboratories, Inc., 6201 South Freeway, Fort Worth, TX 76134-2099 (US).</p>		<p>(81) Designated States: AU, BR, CA, CN, JP, KR, MX, TR, US, ZA, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).</p> <p>Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
(54) Title: TREATMENT OF DISORDERS OF THE OUTER RETINA		
<p>(57) Abstract</p> <p>Compositions and methods for treating disorders of the outer retina with glutamate antagonists are disclosed.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

TREATMENT OF DISORDERS OF THE OUTER RETINA

This invention is directed to the use of glutamate antagonists to treat disorders of the outer retina.

Background Of The Invention

The pathogenesis of retinal degenerative diseases such as age-related macular degeneration (ARMD) and retinitis pigmentosa (RP) is multifaceted and can be triggered by environmental factors in those who are genetically predisposed. One such environmental factor, light exposure, has been identified as a contributing factor to the progression of retinal degenerative disorders such as ARMD (*Sur Ophthalmol*, 1988, 32, 252-269). Photo-oxidative stress leading to light damage to retinal cells has been shown to be a useful model for studying retinal degenerative diseases for the following reasons: damage is primarily to the photoreceptors and retinal pigment epithelium of the outer retina (*Invest Ophthalmol & Vis Sci*, 1966, 5, 450-472; *Sur Ophthalmol*, 1988, 32, 375-413; *Invest Ophthalmol & Vis Sci*, 1996, 37, 1236-1249); they share a common mechanism of cell death, apoptosis (*Trans AM Ophthalmol Soc*, 1996, 94, 411-430; *Res Commun Mol Pathol Pharmacol*, 1996, 92, 177-189); light has been implicated as an environmental risk factor for progression of ARMD and RP (*Arch Ophthalmol*, 1992, 110, 99-104; *Invest Ophthalmol & Vis Sci*, 1996, 37, 775-782); and therapeutic interventions which inhibit photo-oxidative injury have also been shown to be effective in animal models of hereditary degenerative retinal disease (*Proc Nat Acad Sci*, 1992, 89, 11249-11253; *Nature*, 1990, 347, 83-86).

A number of different classes of compounds have been reported to minimize retinal photic injury in various animal models: antioxidants, such as, ascorbate (*Invest Ophthalmol & Vis Sci*, 1985, 26, 1589-1598), dimethylthiourea (*Invest Ophthalmol & Vis Sci*, 1992, 33, 450-472; *Arch Ophthalmol*, 1990, 108, 1751-1752), α -tocopherol (*Nippon Ganka Gakkai Zasshi*, 1994, 98, 948-954), and β -carotene (*Cur Eye Res*, 1995, 15, 219-232); calcium antagonists, such as, flunarizine, (*Exp Eye Res*, 1993, 56, 71-78, *Arch Ophthalmol*,

1992, 109, 554-622); growth factors, such as, basic-fibroblast growth factor, brain derived nerve factor, ciliary neurotrophic factor, and interleukin-1- β (*Proc Nat Acad Sci*, 1992, 89, 11249-11253); glucocorticoids, such as, methylprednisolone (*Graefes Arch Clin Exp Ophthalmol*, 1993, 231, 729-736), dexamethasone (*Exp Eye Res*, 1992, 54, 583-594); and iron chelators, such as, desferrioxamine (*Cur Eye Res*, 1991, 2, 133-144).

To date, excitatory amino acid antagonists have not been evaluated in models of outer retinal degeneration as several studies have demonstrated that principally inner retinal cells are sensitive to excitatory amino acid toxicity, while exposure to excitatory amino acids has no effect on outer retina photoreceptors and retinal pigment epithelial (RPE) cells (*Exp Brain Res*, 1995, 106, 93-105; *Vis Neurosci*, 1992, 8, 567-573). However, when tested in a model of mechanical stress induced ischemia reperfusion, inner retina function and RPE function were moderately protected by dextromethorphan treatment but no significant protective effect was measured for outer retina function (*Arch Ophthalmol*, 1993, 111, 384-388). Similarly, MK-801 was found to be minimally effective at 60 days in preventing the spread of laser induced thermal burns to the retina, but did not significantly prevent photoreceptor loss when evaluated at 3 and 20 days post laser exposure (*Invest Ophthalmol & Vis Sci*, 1997, 38, 1380-1389).

A series of N-methyl-D-aspartate (NMDA) antagonists including eliprodil, ifenprodil, CP-101,606, tibalosine, 2309BT, 840S, and related structural analogs are effective neuroprotectants that are believed to modulate excitatory amino acid toxicity by interacting at the polyamine binding site of the NMDA receptor (*Journal of Pharmacology and Experimental Therapeutic*, 1990, 253, 475-482, *British Journal of Pharmacology*, 1995, 114, 1359-64, *Bioorganic & Medicinal Chemistry Letters*, 1993, 13, 91-94, *Journal of Medicinal Chemistry*, 1995, 38, 3138-45, *Journal of Medicinal Chemistry*, 1998, 41, 1172-1184, *Journal of Medicinal Chemistry*, 1991, 34, 3085-3090, WO 97/09309 Synthelabo, WO 97/09310 Synthelabo). More specifically ifenprodil, eliprodil, and CP-101,606 have recently been shown to preferentially block to the NR1A/NR2B subtype of the polyamine binding site of the NMDA receptor (*Neuroscience Letters*, 1997, 223, 133-136, *Journal of Pharmacology and Experimental Therapeutic*, 1996, 279, 515-523). The selective interaction of the compounds with the

polyamine site of the NMDA receptor subunit is believed to be responsible at least in part for both the neuroprotective activity and the relatively favorable side effects profile of this class of compounds when compared to NMDA antagonists that act at other sites on the NMDA receptor, such as MK-801 and PCP.

5 In addition to having activity as NMDA antagonists, certain compounds, such as, eliprodil and ifenprodil, have calcium antagonist activity at both the calcium, N, P, and L channels. (*European Journal of Pharmacology*, 1996, 299, 103-112, *European Journal of Pharmacology*, 1994, 257, 297-301). Other calcium antagonists, such as, flunarizine,
10 have also been shown to be protective in light induced damage models (*Exp Eye Res*, 1993, 56, 71-78; *Arch Ophthalmol*, 109, 1991, 554-62).

Brief Description of the Drawings

15 **Figure 1** shows the prevention of photic retinopathy by eliprodil and other glutamate agonists.






Figure 2 shows protection of the retina from collateral damage due to laser treatment.

20 **Figure 3** shows the prevention of collateral retinal laser burn damage by eliprodil and its enantiomers.

The present invention is directed to glutamate antagonists which have been discovered to be useful in treating disorders of the outer retina, particularly: age-related macular degeneration; retinitis pigmentosa and other forms of hereditary degenerative retinal
25 disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; damage associated with laser therapy (grid, focal and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery or vitrectomy) or light induced iatrogenic retinopathy; and preservation of retinal transplants. As used herein the outer retina includes the RPE, photoreceptors, Muller cells (to the extent they
30 are found in the outer retina), and the outer plexiform layer. The compounds are formulated for systemic or local ocular delivery.

In our light damage paradigms, antioxidants were either ineffective (alpha-tocopherol) or marginally effective at high doses (ascorbate, vitamin E analogs). Similarly, some calcium antagonists (flunarizine, nicardipine) were moderately effective while others (nifedipine, nimodipine, barnidipine, verapamil, lidoflazine, prenylamine lactate, amiloride) had no effect in preventing light induced functional or morphological changes. However, it has been discovered that NMDA antagonists are effective in treating disorders of the outer retina.

As used herein the term glutamate antagonist means antagonist of the NMDA receptor channel complex. NMDA receptor antagonists include channel blockers (agents that operate uncompetitively to block the NMDA receptor channel); receptor antagonists (agents that compete with NMDA or glutamate at the NMDA binding site; agents acting at the glycine coagonist site or any of several modulation sites (e.g., zinc, magnesiums, redox, or polyamine sites). Disorders of the outer retina encompasses acute and chronic environmentally induced (trauma, ischemia, photo-oxidative stress) degenerative conditions of the outer retina (retinal pigment epithelial cells "RPE cells") in genetically predisposed individuals. This would include, but not be limited to, age-related macular degeneration, retinitis pigmentosa and other forms of hereditary degenerative retinal disease, retinal detachment, tears, macular pucker, ischemia affecting the outer retina, damage associated with laser therapy (grid, focal and panretinal) including photodynamic therapy (PDT), trauma, surgical (retinal translocation, subretinal surgery or vitrectomy) or light induced iatrogenic retinopathy and preservation of retinal transplants. Preferred glutamate antagonists inhibit excitotoxicity by binding at the polyamine site and have calcium antagonist and/or sodium antagonist, and/or neurotrophic activity. The glutamate antagonists which have been found to be particularly effective have the following structure.



Y, X = OH, H

m = 0-3

n, p = 1, 2

R¹ = H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16

alkanoyloxy, benzoyloxy or when R² = OH or methoxy in the 4-position and R³ = H then

R¹ = hydroxymethyl, carbamoyl, or C1-4 alkoxycarbonyl;

R² = H, halogen, C1-4 alkyl, OH, C1-4 alkoxy;

R³, R⁴ = H, C1-4 alkyl; and

R⁵ = H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16 alkanoyloxy, benzoyloxy.

These compounds include all isomers and pharmaceutically acceptable salts.

In the preferred embodiments the glutamate antagonist is 2-[4-(4-fluorobenzyl)-piperidino]-1-(4-chlorophenyl)ethanol (eliprodil) and/or its R or S isomers.

Certain compounds of this invention have also been shown to have a neurotrophic effect see U.S. Patent No. 5,547,963. Since it has been shown that nerve growth factor

inhibits retinal degeneration in a mouse strain genetically predisposed to retinal degeneration (*Graefes Arch Clin and Exp Ophthal*, 1996, 234 supplement 1, S96-100) the neurotrophic activity of the compounds of this invention may provide an additional therapeutic effect.

5

In general, for degenerative diseases, the compounds of this invention are administered orally with daily dosage of these compounds ranging between 0.01 and 500 milligrams. The preferred total daily dose ranges between 1 and 100 milligrams. Non-oral administration, such as, intravitreal, topical ocular, transdermal patch, parenteral, 10 intraocular, subconjunctival, or retrobulbar injection, iontophoresis or slow release biodegradable polymers or liposomes may require an adjustment of the total daily dose necessary to provide a therapeutically effective amount of the compound. The compounds can also be delivered in ocular irrigating solutions used during surgery see U.S. Patent No. 5,604,244 for irrigating solution formulations. This patent is herein 15 incorporated by reference. Concentrations should range from 0.001 μM to 10 μM , preferably 0.01 μM to 5 μM .

20

25

30

The compounds can be incorporated into various types of ophthalmic formulations for topical delivery to the eye. They may be combined with ophthalmologically acceptable preservatives, surfactants, viscosity enhancers, penetration enhancers, buffers, sodium chloride, and water to form aqueous, sterile ophthalmic suspensions or solutions. Ophthalmic solution formulations may be prepared by dissolving the compound in a physiologically acceptable isotonic aqueous buffer. Further, the ophthalmic solution may include an ophthalmologically acceptable surfactant to assist in dissolving the compound. The ophthalmic solutions may contain a thickener, such as, hydroxymethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, methylcellulose, polyvinyl-pyrrolidone, or the like, to improve the retention of the formulation in the conjunctival sac. In order to prepare sterile ophthalmic ointment formulations, the active ingredient is combined with a preservative in an appropriate vehicle, such as, mineral oil, liquid lanolin, or white petrolatum. Sterile ophthalmic gel formulations may be prepared by suspending the active ingredient in a hydrophilic base prepared from the combination of, for example, carbopol-940, or the like, according to

the published formulations for analogous ophthalmic preparations; preservatives and tonicity agents can be incorporated.

If dosed topically, the compounds are preferably formulated as topical ophthalmic suspensions or solutions, with a pH of about 4 to 8. The compounds will normally be contained in these formulations in an amount .001% to 5% by weight, but preferably in an amount of .01% to 2% by weight. Thus, for topical presentation, 1 to 2 drops of these formulations would be delivered to the surface of the eye 1 to 4 times per day according to the routine discretion of a skilled clinician.

The preferred compound, eliprodil (or its R or S isomers), is orally bioavailable, demonstrates a low incidence of adverse effects upon administration, and effectively crosses the blood-brain barrier (*Drugs of the Future*, 1994, 19, 905-909) indicating that effective concentrations are expected in the target tissue, the retina. The compound is described in U.S. Patent No. 4,690,931, the contents of which are incorporated herein by reference.

Eliprodil was evaluated in our light induced damage paradigm, a model of retinal degenerative diseases such as retinitis pigmentosa and age-related macular degeneration. Unexpectedly eliprodil, an excitatory amino acid antagonist, demonstrated marked potency and efficacy as a cytoprotective agent. Both photoreceptor and RPE cells were completely protected from light induced functional changes and morphologic lesions.

EXAMPLE 1

Photo-oxidative Induced Retinopathy

Photic retinopathy results from excessive excitation of the retinal pigment epithelium and neuroretina by absorption of visible or near ultraviolet radiation. Lesion severity is dependent upon wavelength, irradiance, exposure duration, species, ocular pigmentation, and age. Damage may result from peroxidation of cellular membranes, inactivation of mitochondrial enzymes such as cytochrome oxidase, or increased intracellular calcium. Cellular damage resulting from photo-oxidative stress leads to cell

death by apoptosis, (Shahinfar, S., Edward, D. P. and Tso, M. O. (1991), A pathologic study of photoreceptor cell death in retinal photic injury. *Current Eye Research*, 10:47-59; Abler, A. S., Chang, C. J., Fu, J. and Tso, M. O. (1994), Photic injury triggers apoptosis of photoreceptor cells. *Investigative Ophthalmology & Visual Science*, 35(Suppl):1517). Oxidative stress induced apoptosis has been implicated as a cause of many ocular pathologies, including, iatrogenic retinopathy, macular degeneration, retinitis pigmentosa and other forms of hereditary degenerative disease, ischemic retinopathy, retinal tears, retinal detachment, glaucoma and retinal neovascularization (Chang, C. J., Lai, W. W., Edward, D. P. and Tso, M. O. (1995), Apoptotic photoreceptor cell death after traumatic retinal detachment in humans, *Archives of Ophthalmology*, 113:880-886; Portera-Cailliau, C., Sung, C. H., Nathans, J. and Adler, R. (1994), Apoptotic photoreceptor cell death in mouse models of retinitis pigmentosa, *Proceedings of National Academy of Science (U.S.A.)*, 91:974-978; Buchi, E. R. (1992), Cell death in the rat retina after a pressure-induced ischaemia-reperfusion insult: an electron microscopic study. I. Ganglion cell layer and inner nuclear layer, *Experimental Eye Research*, 55:605-613; Quigley, H. A., Nickells, R. W., Kerrigan, L. A., Pease, M. E., Thibault, D. J. and Zack, D. J. (1995), Retinal ganglion cell death in experimental glaucoma and after axotomy occurs by apoptosis, *Investigative Ophthalmology & Visual Science*, 36:774-786). Photic induced retinal damage has been observed in mice (Zigman, S., Groff, J., Yulo, T. and Vaughan, T. (1975), The response of mouse ocular tissues to continuous near-UV light exposure. *Investigative Ophthalmology & Visual Science*, 14:710-713), rats (Noell, W. K., Walker, V. S., Kang, B. S., and Berman, S. (1966), Retinal damage by light in rats, *Investigative Ophthalmology and Visual Science*, 5:450-473; Kuwabara, T. and Gorn, R. A. (1968), Retinal damage by visible light: An electron microscopic study, *Archives of Ophthalmology*, 79:69-78; LaVail, M. M. (1976), Survival of some photoreceptor cells in albino rats following long-term exposure to continuous light, *Investigative Ophthalmology & Visual Science*, 15:64-70), rabbit (Lawwill, T. (1973), Effects of prolonged exposure of rabbit retina to low-intensity light, *Investigative Ophthalmology & Visual Science*, 12:45-51), squirrel (Collier, R. J. and Zigman, S. (1989), Comparison of retinal photochemical lesions after exposure to Near-UV or short-wavelength visible radiation, In M. M. LaVail, R. E. Anderson, and J. G. Hollyfield (Eds.), *Inherited and Environmentally induced Retinal Degenerations*.

Alan R. Liss, Inc., New York; Collier, R., W. Waldron and Zigman, S. (1989), Temporal sequence of changes to the gray squirrel retina after near-UV exposure, *Investigative Ophthalmology & Visual Science*, 30:631-637), non-human primates (Tso, M. O. M. (1973), Photic maculopathy in rhesus monkey. A light and electron microscopic study. *Investigative Ophthalmology & Visual Science*, 12:17-34; Ham, W. T., Jr., Ruffolo, J. J., Jr., Mueller, H. A. and Guerry, D., III. (1980), The nature of retinal radiation damage: dependence on wavelength, power level and exposure time, *Vision Research*, 20:1105-1111; Sperling, H. G., Johnson, C. and Harwerth, R. S. (1980), Differential spectral photic damage to primate cones, *Vision Research*, 20:1117-1125; Sykes, S. M., Robison, W. G., Jr., Waxler, M. and Kuwabara, T. (1981), Damage to the monkey retina by broad spectrum fluorescent light, *Investigative Ophthalmology & Visual Science*, 20:425-434; Lawwill, T. (1982), Three major pathologic processes caused by light in the primate retina: A search for mechanisms, *Transactions of the American Ophthalmology Society*, 80:517-577), and man (Marshall, J., Hamilton, A. M. and Bird, A. C. (1975), Histopathology of ruby and argon laser lesions in monkey and human retina, *British Journal of Ophthalmology*, 59:610-630; Green, W. R. and Robertson, D. M. (1991), Pathologic findings of photic retinopathy in the human eye. *American Journal of Ophthalmology*, 112:520-27). In man, chronic exposure to environmental radiation has also been implicated as a risk factor for age-related macular degeneration (Young, R. W. (1988), Solar radiation and age-related macular degeneration, *Survey of Ophthalmology*, 32:252-269; Taylor, H. R., West, S., Munoz, B., Rosenthal, F. S., Bressler, S. B. and Bressler, N. M. (1992), The long-term effects of visible light on the eye, *Archives of Ophthalmology*, 110:99-104; Cruickshanks, K. J., Klein, R. and Klein, E. K. (1993), Sunlight and age-related macular degeneration. The Beaver Dam Eye Study, *Archives of Ophthalmology*, 111:514-518).

To determine if eliprodil and other glutamate antagonists can rescue retinal cells from photo-oxidative insult, male Sprague Dawley rats were randomly assigned to drug or vehicle experimental groups. In Experiment 1, rats were dosed with various glutamate antagonists, including: MK-801; eliprodil; and memantine and in Experiment 2, the potency of eliprodil was compared to the potency of its isomers. In both experiments, rats received three intra peritoneal (IP) injections of either vehicle or drug at 48, 24, and 0

hours prior to a 6-hour light exposure to spectrally filtered blue light (~220 fc). Control rats were housed in their home cage under normal cyclic light exposure. The electroretinogram (ERG) is a non-invasive clinical measurement of the electrical response of the eye to a flash of light. The a-wave and b-wave are two components of the ERG that are diagnostic of retinal function. The a-wave reflects outer retina function and is generated by interactions between photoreceptor and pigment epithelial cells while the b-wave reflects inner retina function, particularly Muller cells. The ERG was recorded after a five day recovery period from dark-adapted anesthetized rats (Ketamine-HCl, 75 mg/Kg; Xylazine, 6 mg/Kg). The eyes' electrical response to a flash of light was elicited by viewing a ganzfeld. ERGs to a series of light flashes increasing in intensity were digitized to analyze temporal characteristics of the waveform and response voltage-log intensity (VlogI) relationship.

Results:

Effect of blue-light exposure on vehicle dosed rats: Blue-light exposure for 6 hours resulted in a significant diminution of the ERG response amplitude (ANOVA, $p < 0.001$; Bonferroni t-test, $p < 0.05$) compared to controls when measured after a 5-day recovery period (Figure 1-A). Maximum a-wave and b-wave amplitudes were reduced more than 70% in vehicle-dosed rats compared to controls. In addition, threshold responses were lower and evoked at brighter flash intensities.

Experiment 1: Prevention of photic retinopathy with glutamate antagonists:

Rats dosed with MK-801, eliprodil or memantine showed dose-dependent protection of outer and inner retina function against this photo-oxidative induced retinopathy

- 1.) **MK-801.** MK-801 provided significant protection of outer and inner retina function against light induced retinal degeneration in rats dosed with 20 mg/kg. Further, response amplitudes, waveforms, and threshold responses were not significantly different than control. Maximum a-wave response amplitudes averaged 734.05 μV (SEM=36.79 μV) from controls and 537.93 μV (SEM=34.42 μV) from 20 mg/kg dosed rats (See Figure 1-A). Similarly,

maximum b-wave response amplitudes were not significantly different and averaged 1807 μ V (SEM=74.32 μ V) from controls and 1449.77 μ V (SEM=68.12 μ V) from MK-801 dosed rats. No significant protection of retinal function was measured in rats dosed with MK-801 at doses of 2 or 10 mg/kg.

5
2.) **Eliprodil.** Significant preservation of retinal function was also measured in eliprodil (racemic mixture) dosed rats (20 mg/kg) compared to vehicles (Figure 1-A). The ERG a- and b-wave were 57% and 53% of normal and 2.4 and 2.2 fold higher than vehicle dosed rats, respectively. ERGs recorded from rats dosed with eliprodil (2 or 10 mg/kg) were not significantly different than vehicles and approximately 32% of normal.

10
3.) **Memantine.** As shown in Figure 1-A, no significant protection of outer and inner retina function was measured in memantine (2 mg/kg) dosed rats. Memantine provided significant protection of outer and inner retina function against light induced retinal degeneration in rats dosed with 20 mg/kg compared to vehicle dosed rats. However, ERG responses were significantly lower than normal in rats dosed with 20 mg/kg.

15
20 **Experiment 2: Comparison of eliprodil with the R and S isomer:**

1.) **Eliprodil.** Eliprodil (racemic) provided significant protection of outer and inner retina function against light induced retinal degeneration in rats dosed with 20 and 40 mg/kg (Figure 1-B). Maximum a-wave response amplitudes in eliprodil dosed rats with 20 and 40 mg/kg were 2.4 and 2.25 fold higher, respectively, than vehicle dosed rats. After a 5-day recovery period, maximum a-wave response amplitudes averaged 395.82 μ V (SEM=46.4 μ V) from 20 mg/kg dosed rats and 419.85 μ V (SEM=63.88 μ V) from 40 mg/kg dosed rats. No significant difference in retinal function was detected between either dose group and these amplitudes were approximately 60% of normal.

25
30
2.) **R-eliprodil.** As seen in Figure 1-B, R-eliprodil was two-fold less potent than

eliprodil (racemic). No significant protection of outer and inner retina function was measured after a 5-day recovery period in rats dosed with R-eliprodil at 20 mg/kg. Maximum a- and b-wave responses were 38% and 36% of normal, respectively. However, R-eliprodil did provide significant protection of outer and inner retina function against light induced retinal degeneration in rats dosed with 40 mg/kg (Figure 1-B). Response amplitudes were about 2 fold higher than vehicle dosed rats and 50% of normal. Maximum a- and b-wave response amplitudes averaged 397.25 μ V (SEM=77.14 μ V) and 812.87 μ V (SEM=160.13 μ V), respectively. No significant retinal protection was measured in rats dosed with the highest dose of R-eliprodil, 80 mg/kg. Maximum a- and b-wave responses were approximately 40% of normal.

3.) **S-eliprodil.** No significant difference in ERG response amplitude was measured between S-eliprodil (5 mg/kg) dosed rats compared to vehicle dosed rats. However, as seen in Figure 1-B, S-eliprodil was two-fold more potent than eliprodil (racemic). Significant protection of outer and inner retina function was measured after a 5-day recovery period in rats dosed with S-eliprodil as low as 10 mg/kg compared to vehicles. Maximum a- and b-wave responses were 64% and 76% of normal, respectively. Significant protection of outer and inner retina function against light induced retinal degeneration compared to vehicle dosed rats was also measured in rats dosed with 20 mg/kg. Response amplitudes were about 2 fold higher than vehicle dosed rats and approximately 62% of normal after a 5-day recovery period. Maximum a- and b-wave response amplitudes averaged 418.04 μ V (SEM=56.18 μ V) and 1015.95 μ V (SEM=141.49 μ V), respectively.

Summary:

All glutamate antagonists evaluated from this series of compounds provided significant rescue of RPE and photoreceptor cells in this photic induced retinopathy model. Complete protection was measured in MK-801 dosed rats. The S-enantiomer was the most potent retinoprotective agent in this series of glutamate antagonists.

EXAMPLE 2

Retinal Laser Burn Spread Damage

The eye is exposed to high-energy laser radiation during the performance of retinal photocoagulation therapy (grid, focal and panretinal) or during photodynamic therapy. This type of therapy is often employed during treatment of choroidal neovascularization, proliferative stages of diabetic retinopathy, retinopathy of prematurity, or to repair retinal holes or detachments. Associated with this laser therapy is tissue destruction leading to vision deterioration. The Macular Photocoagulation Study found that 20% of the eyes treated for subfoveal macular choroidal neovascularizations (CNV) and 18% of the eyes treated for juxtafoveal CNV suffered severe visual loss of six or more lines as a direct result of laser treatment. It is believed that this vision loss results directly from the expansion of the laser-induced lesion to surrounding normal neurosensory retina and RPE. Singlet oxygen and other reactive oxygen species as well as cytokines are generated in the area of the laser burn and thought to migrate laterally to cause collateral retinal damage. Retinal morphology changes in this area are similar to changes in our photo-oxidative retinopathy paradigm.

The objective of this study was to quantitate change in laser burn size in vehicle dosed or eliprodil dosed rats to determine if therapeutic agents could minimize laser burn spread damage. Pigmented Long Evans rats were randomly assigned to control, vehicle or drug dosed groups. Rats were pre dosed (IP) 64, 48, 24, and 2 hours before lasering and 3, 19 and 25 hours after receiving 2 to 4 laser burns from an argon laser (spot size = 200-microns, power intensity = 100 mW, and exposure duration = 0.1 seconds). After a 48-hour recovery period, eyes were fixed, dehydrated, and embedded in plastic resin. Histological assessment of laser burns was performed by flatmounting the retina and sectioning the tissue in a plane tangential to the nerve fiber layer. Using this technique, the lesion area in the outer nuclear layer could be calculated using an image analysis system.

Results:

Histological assessment of retinal burns 48 hours after laser exposure showed that

lesions were normally confined to the choriocapillaris, retinal pigment epithelium and outer retina. The laser burn center was marked by: complete closure of all capillaries, arterioles and venules; perforation of Bruch's membrane; pyknosis and necrosis of all photoreceptor nuclei; and destruction of inner and outer segments. Spread of the lesion into peripheral retina consisted of shortening of outer segments, inner segment swelling, clumping of melanin granules in the RPE and choroid, and vacuolization of the RPE. In control and vehicle-dosed eyes, laser burn areas averaged 50,627.07 and 55,243.65 μ^2 , respectively (Figures 2, 3).

1.) **Eliprodil.** Treatment with eliprodil (racemic) significantly reduced the retinal burn area approximately 60% (Figures 2, 3) compared to vehicle. The average burn area in eliprodil dosed rats was 22,406 μ^2 (SEM=3559.3 μ^2). No reduction in laser lesion burn size was measured in rats dosed with 10 mg/kg. Laser burn lesion areas averaged 55,411.67 μ^2 (SEM=2555.47 μ^2) in this group of rats.

2.) **R-eliprodil.** Dosing with R-eliprodil (40 mg/kg) resulted in lesion areas that were 28% smaller than lesions in vehicle dosed rats. Laser burn lesion areas in R-eliprodil dosed rats averaged 36,016 μ^2 (SEM=4779.49 μ^2) and were significantly different than vehicle dosed or non-injected lesions (Figure 3). Dosing with R-eliprodil (20 mg/kg) resulted in laser lesion areas that were 16% smaller than lesions measured in vehicle dosed rats but were not significantly different.

3.) **S-eliprodil.** Laser burn lesion areas in S-eliprodil (20 mg/kg) dosed rats averaged 43,098.5 μ^2 (SEM=2992.94 μ^2). Lesion area was 15% smaller than lesion areas in vehicle dosed rats but were not significantly different than vehicle controls (Figure 3).

Summary:

Both the R-isomer and the racemic mixture of eliprodil provided significant reduction of collateral retinal damage around the laser burn. Eliprodil (racemic) was found to be two fold more potent and twice as efficacious in this laser burn spread model

compared to R-eliprodil. Both of these molecules have nanomolar binding affinities to the NMDA receptor, compared to S-eliprodil, which was devoid of significant efficacy in this model and has millimolar affinity to the NMDA receptor.

The following formulations are representative and not limiting.

EXAMPLE 3

1.0% Eliprodil Suspension w/v %	
Eliprodil	1%
Hydroxypropyl methylcellulose	0.5%
Dibasic sodium phosphate (anhydrous)	0.2%
Sodium chloride	0.75%
Disodium EDTA (edetate disodium)	0.01%
Polysorbate 80	0.05%
Benzalkonium chloride solution	0.01% +5%xs
Sodium hydroxide	adjust to pH 5
Hydrochloric acid	adjust to pH 5
Water for injection	q.s. to 100%
Target Tonicity = 290 mOsm/Kg	Target pH = 5

EXAMPLE 4

3.0% Eliprodil Suspension w/v %	
Eliprodil	3.3%
Sodium chloride	0.9%
Polysorbate 80	0.1%
Water for injection	q.s. to 100%

5

EXAMPLE 5

10mM IV Solution w/v %	
Glutamate antagonist	0.384%
L-Tartaric acid	2.31%
Sodium hydroxide	pH 3.8
Hydrochloric acid	pH 3.8
Purified water	q.s. 100%

EXAMPLE 6

10

0.3% Solution w/v %	
Glutamate antagonist	0.33%
Sodium acetate	0.07%
Mannitol	4.3%
Disodium EDTA (edetate disodium)	0.1%
Benzalkonium chloride solution	0.01%
Sodium hydroxide	pH 4.0
Hydrochloric acid	pH 4.0
Purified water	q.s. 100%

EXAMPLE 7

R-Eliprodil 5 mg Capsules		
Ingredient	mg/capsule (Total Wt. 221 mg)	% w/w
R-Eliprodil hydrochloride	5.53 ¹	2.5%
Lactose	206.67	93.52%
Sodium starch glycolate	6.6	2.98%
Magnesium stearate	2.2	1.00%

¹Equivalent to 5 mg Eliprodil as free base.

5

EXAMPLE 8

S-Eliprodil 50 mg Capsules		
Ingredient	mg/capsule (Total Wt. 221 mg)	% w/w
S-Eliprodil hydrochloride	55.25 ¹	25%
Lactose (monohydrate)	156.95	71.02%
Sodium starch glycolate	6.6	2.98%
Magnesium stearate	2.2	1.00%

¹Equivalent to 50 mg Eliprodil as free base.

10

EXAMPLE 9

R-Eliprodil 10 mg Capsules		
Ingredient	mg/capsule (Total Wt. 221 mg)	% w/w
R-Eliprodil hydrochloride	11.05 ¹	5%
Lactose (monohydrate)	201.15	91.02%
Sodium starch glycolate	6.6	2.98%
Magnesium stearate	2.2	1.00%

¹Equivalent to 10 mg Eliprodil as free base.

EXAMPLE 10

Eliprodil 20 mg Capsules		
Ingredient	mg/capsule (Total Wt. 221 mg)	% w/w
Eliprodil hydrochloride	22.1 ¹	10%
Lactose	190.1	86.02%
Sodium starch glycolate	6.6	2.98%
Magnesium stearate	2.2	1.00%


¹Equivalent to 20 mg Eliprodil as free base.

We Claim:

1. A composition for the treatment of disorders of the outer retina comprising a pharmaceutically effective amount of a glutamate antagonist.

2. The composition of Claim 1 wherein the glutamate antagonist is a polyamine site antagonist.

3. The composition of Claim 1 wherein the glutamate antagonist is a compound of the formula:



Y, X = OH, H

m = 0-3

n, p = 1, 2

R¹ = H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16 alkanoyloxy, benzoyloxy or when R² = OH or methoxy in the 4-position and R³ = H then R¹ = hydroxymethyl, carbamoyl, or C1-4 alkoxycarbonyl;

R² = H, halogen, C1-4 alkyl, OH, C1-4 alkoxy;







R³, R⁴ = H, C1-4 alkyl; and

R⁵ = H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16

alkanoyloxy, benzoyloxy.

in a pharmaceutically acceptable carrier.

- 5 4. The composition of Claim 3 wherein the compound is eliprodil.
5. The composition of Claim 3 wherein the compound is the R or S isomer
of eliprodil.
- 10 6. The composition of Claim 1 wherein the disorder is selected from the
group consisting of: age-related macular degeneration; retinitis pigmentosa and other
forms of heredodegenerative retinal disease; retinal detachment and tears; macular
pucker; ischemia affecting the outer retina; damage associated with laser therapy (grid,
focal and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal
15 translocation, subretinal surgery or vitrectomy) or light induced iatrogenic retinopathy;
and preservation of retinal transplants.
7. The composition of Claim 6 wherein the compound is eliprodil.
- 20 8. The composition of Claim 7 wherein the compound is the R or S isomer
of eliprodil.
9. A method for treating disorders of the outer retina which comprises
administering a pharmaceutically effective amount of a glutamate antagonist.
- 25 10. The method of Claim 9 wherein the glutamate antagonist is a polyamine
site antagonist.
11. The method of Claim 9 wherein the glutamate antagonist is a compound
30 of the formula:



Y, X = OH, H

m = 0-3

n, p = 1, 2

R¹ = H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16 alkanoyloxy, benzoyloxy or when R² = OH or methoxy in the 4-position and R³ = H then R¹ = hydroxymethyl, carbamoyl, or C1-4 alkoxy carbonyl;

R² = H, halogen, C1-4 alkyl, OH, C1-4 alkoxy;

R³, R⁴ = H, C1-4 alkyl; and

R⁵ = H, halogen, trifluoromethyl, C1-4 alkyl, OH, C1-4 alkoxy, benzyloxy, C1-16 alkanoyloxy, benzoyloxy.

in a pharmaceutically acceptable carrier.

12. The method of Claim 11 wherein the compound is eliprodiol.

13. The method of Claim 12 wherein the compound is R or S eliprodiol.

14. The method of Claim 9 wherein the disorder is selected from the group consisting of: age-related macular degeneration; retinitis pigmentosa and other forms of hereditary degenerative retinal disease; retinal detachment and tears; macular pucker;


ischemia affecting the outer retina; damage associated with laser therapy (grid, focal and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery or vitrectomy) or light induced iatrogenic retinopathy; and preservation of retinal transplants.

5

15. The method of Claim 14 wherein the compound is eliprodil or its R or S isomer.

10

FIGURE 1



* Significantly higher amplitude compared to vehicle ($p < 0.05$).

2/3

FIGURE 2





FIGURE 3



- * Significantly smaller lesion area compared to Vehicle ($p < 0.05$).
- ♦ Dose providing significant protection against photic induced retinopathy.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/24502

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/445

US CL : 514/317

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/317

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONEElectronic data base consulted during the international search (name of data base and, where practicable, search terms used)
APS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,710,165 A (KAPIN et al.) 20 January 1998, see the entire document.	1-11

☐

Further documents are listed in the continuation of Box C.

☐

See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
I document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means	
P document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

04 FEBRUARY 2000

Date of mailing of the international search report

23 FEB 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

ZOHREH FAY

Telephone No. (703) 308-1235